Hallucinogen Addiction Treatment in Tennessee | Brooks Healing Center
Hallucinogen addiction can profoundly impact your life, altering perceptions and straining relationships. At Brooks Healing Center in Tennessee, we offer compassionate, evidence-based treatment for people struggling with problematic hallucinogen use, substance use disorders, and co-occurring mental health symptoms that can be safely managed within our substance use treatment setting.
Our team understands the unique challenges posed by substances such as LSD, psilocybin, PCP, ketamine, and other psychedelic or dissociative drugs. These substances do not all work the same way or carry identical risks, which is why treatment should be based on the actual drug involved, pattern of use, mental health symptoms, other substances, and the individual’s overall clinical needs.
Brooks Healing Center provides hallucinogen addiction treatment between Nashville and Chattanooga in Normandy, Tennessee. Depending on clinical needs, care can include assessment and stabilization, residential addiction treatment, individualized therapy, support for appropriate co-occurring mental health symptoms, Partial Hospitalization Program (PHP), and sober living.
Call Admissions 24/7: (931) 486-8824
Table of Contents
Key Points About Hallucinogen Addiction and Treatment
- Hallucinogens are a diverse group of substances rather than one drug class with one risk profile. Classic psychedelics such as LSD and psilocybin differ substantially from dissociative drugs such as PCP and ketamine.
- Classic psychedelics generally do not produce the same pattern of physical dependence and withdrawal seen with alcohol, opioids, or benzodiazepines. However, tolerance, psychological distress, risky behavior, and problematic patterns of use can still occur.
- PCP and other dissociatives can present differently. PCP can be addictive and withdrawal symptoms have been documented, including anxiety, agitation, hallucinations, abnormal muscle activity, increased body temperature, and seizures.
- Ketamine also carries misuse and dependence risks. Repeated ketamine exposure can additionally cause urinary and bladder complications and other health problems.
- Hallucinogen intoxication can become a medical emergency. Severe agitation, psychosis, seizures, loss of consciousness, accidents, dangerous behavior, or significant physiological effects may require emergency care.
- Direct fatal toxicity from classic psychedelics such as LSD or psilocybin is uncommon, but that does not make use risk-free. PCP and ketamine can cause much more severe physiological toxicity, including coma, seizures, respiratory depression, and death.
- Approximately 9.1 million Americans age 12 or older reported past-year hallucinogen use in 2025.
- How Brooks helps: Brooks provides assessment and stabilization when clinically appropriate, residential addiction treatment, individualized therapy, support for co-occurring mental health symptoms appropriate for our substance use treatment setting, PHP, supportive housing, sober living, and continuing recovery planning.
Hallucinogen Addiction Treatment at a Glance
| Brooks Program / Level of Care | What It Provides | When It May Be Appropriate |
|---|---|---|
| Assessment & Stabilization | Clinical assessment, mental-health monitoring, stabilization, symptom management, and evaluation of other substances. | When recent hallucinogen use involves safely manageable co-occurring symptoms, dissociative-drug dependence, polysubstance use, medical concerns appropriate for the setting, or a need for structured observation. Severe symptoms or medical instability may require hospital care. |
| Residential Treatment | 24/7 staff support with therapy, recovery education, co-occurring symptom support, relapse prevention, individualized care, and access to medical care as needed. | When substance use is difficult to interrupt outside treatment or safely manageable co-occurring symptoms, behavioral concerns, or recovery needs require substantial structure. |
| Behavioral Treatment | Therapy addressing triggers, cravings, coping, trauma when relevant, emotional regulation, substance-use patterns, and relapse prevention. | Throughout treatment for clinically significant hallucinogen or dissociative-drug misuse. |
| Partial Hospitalization Program (PHP) | Intensive daytime clinical treatment with therapy, recovery support, medication management when appropriate, and greater independence. | After residential treatment or when someone is medically stable but continues to need significant structure. |
| Sober Living | Structured, substance-free housing with accountability, peer support, routine, and increasing independence. | For eligible individuals who no longer need intensive clinical treatment but continue to benefit from a recovery-focused environment. |
What Are Hallucinogens?
Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings, thoughts, feelings, and perceptions. These substances can produce profound changes in perception, mood, cognition, and a person’s sense of reality.
Hallucinogens may be naturally occurring compounds found in certain plants and mushrooms or human-made substances produced in laboratories. They are often separated into classic psychedelics and dissociative drugs, although several other substances can have overlapping stimulant, dissociative, or hallucinogenic effects.
Current NIDA information describes psychedelic and dissociative drugs as substances capable of temporarily changing mood, thoughts, and perception. Classic psychedelics frequently affect serotonin signaling, while dissociative drugs such as PCP and ketamine act through different brain systems. (NIDA)
Hallucinations can involve seeing, hearing, or feeling things that seem real but are not actually present. Other experiences may include distorted time, altered sensory perception, dissociation, intense emotional changes, fear, paranoia, or a feeling of being disconnected from the body or environment.
The effects can be unpredictable and may vary substantially depending on:
- The specific drug
- Dose
- Potency
- Other substances involved
- The person’s mental health
- Physical health
- Environment or setting
- Expectations
- Previous experience with the drug
While some people seek these experiences recreationally, spiritually, or for self-exploration, hallucinogen use can lead to psychological distress, accidents, dangerous behavior, worsening mental health symptoms, or problematic patterns of use.
Common Hallucinogenic and Dissociative Drugs
Substances commonly grouped within the broader hallucinogen category include:
- LSD (lysergic acid diethylamide)
- Psilocybin, found in certain mushrooms
- Peyote and mescaline
- DMT (dimethyltryptamine)
- Ayahuasca
- Salvia divinorum
- PCP (phencyclidine)
- Ketamine
- DXM (dextromethorphan)
- MDMA (Ecstasy or Molly)
These drugs should not be treated as pharmacologically interchangeable.
MDMA, for example, has substantial stimulant properties along with effects that can alter perception and emotional experience. NIDA describes MDMA as a synthetic drug with effects similar to stimulants such as methamphetamine, while also noting that some researchers classify it as psychedelic because it can alter visual and time perception. (NIDA)
Classic Psychedelics vs. Dissociative Drugs
| Category | Examples | General Effects |
|---|---|---|
| Classic Psychedelics | LSD, psilocybin, mescaline, DMT | Alter perception, sensory processing, mood, thought, and sense of time; many primarily act through serotonin systems. |
| Dissociative Drugs | PCP, ketamine, high-dose DXM | Can produce detachment from the body or environment, distorted sensory experiences, impaired judgment, numbness, confusion, and hallucinations. |
| Mixed / Other Psychoactive Drugs | MDMA, salvia | Can have stimulant, empathogenic, dissociative, or hallucinogenic properties that do not fit neatly into one category. |
The distinction matters clinically because addiction potential, withdrawal, medical complications, and overdose risk vary considerably between these substances.
Hallucinogen Addiction and Abuse
While hallucinogens can be profoundly disorienting and dangerous, not every substance grouped under the word “hallucinogen” has the same dependence potential.
Classic psychedelic substances such as LSD and psilocybin generally do not produce the same pattern of physical dependence or predictable withdrawal seen with opioids, alcohol, or benzodiazepines. Tolerance can develop rapidly with repeated use of some classic psychedelics, particularly LSD, but tolerance is not the same thing as addiction. (NIDA)
That does not mean these substances cannot be used problematically.
Someone may repeatedly use hallucinogens despite:
- Psychological distress
- Relationship problems
- Work or school consequences
- Accidents
- Worsening mental health symptoms
- Financial problems
- Dangerous behavior
- Repeated unsuccessful attempts to stop
The clinical picture also changes substantially with dissociative drugs.
PCP and Ketamine Can Have Different Addiction Risks
PCP can produce tolerance, compulsive use, and withdrawal symptoms. Current MedlinePlus information on PCP describes withdrawal symptoms including anxiety, agitation, hallucinations, abnormal muscle activity, increased body temperature, and seizures in some people who stop after repeated use. (MedlinePlus)
Ketamine also has recognized misuse and abuse potential. The drug has legitimate medical uses as an anesthetic, but repeated nonmedical exposure can lead to problematic patterns of use and significant physical consequences.
Current prescribing information identifies serious urinary and renal complications associated with recurrent ketamine exposure, including cystitis, reduced bladder capacity, ureteral obstruction, and kidney complications. Liver and biliary injury have also been reported with recurrent use. (Ketamine prescribing information)
The statement “hallucinogens are not physically addictive” is too broad. Classic psychedelics and dissociatives have different dependence profiles, and the statement should not be applied to every dissociative, club drug, or other substance placed under the hallucinogen umbrella.
Signs Hallucinogen Use May Have Become a Problem
Possible warning signs include:
- Repeated use despite negative consequences
- Strong desire or preoccupation with the next experience
- Increasing tolerance
- Taking larger amounts than intended
- Spending increasing time obtaining or recovering from drugs
- Neglecting responsibilities
- Using in dangerous environments
- Continuing despite anxiety, paranoia, or other psychological effects
- Persistent use after frightening or dangerous experiences
- Mixing hallucinogens with other substances
- Difficulty reducing or stopping use
- Repeated intoxication that interferes with everyday life
For PCP, ketamine, MDMA, and other drugs with additional stimulant or dissociative effects, warning signs can also include more recognizable craving, dependence, or withdrawal patterns.
Hallucinogens Quick Reference Chart
| Substance | General Category | Federal Schedule | Common Route(s) |
|---|---|---|---|
| LSD | Classic psychedelic | Schedule I | Oral / blotter |
| Psilocybin | Classic psychedelic | Schedule I | Oral |
| Mescaline / Peyote | Classic psychedelic | Generally Schedule I, with limited legal exceptions involving protected religious peyote use | Oral |
| DMT | Classic psychedelic | Schedule I | Smoked, vaporized, oral in preparations such as ayahuasca |
| PCP | Dissociative | Schedule II | Smoked, swallowed, snorted, injected |
| Ketamine | Dissociative anesthetic | Schedule III | Medical injection; illicit use may involve snorting, swallowing, smoking, or injection |
| MDMA | Stimulant / empathogenic drug with hallucinogenic effects | Schedule I | Oral |
| DXM | Dissociative at high doses | Not federally scheduled as an OTC cough medicine ingredient | Oral |
The broader category therefore does not have one DEA schedule or one route of administration.
How Common Is Hallucinogen Use?
Hallucinogen use has increased compared with several years ago.
According to the 2025 National Survey on Drug Use and Health, approximately 9.1 million Americans age 12 or older, or 3.1%, reported using a hallucinogen during the previous year. That was up from approximately 7.6 million people in 2021. (SAMHSA)
In 2025:
- Approximately 2.2 million young adults ages 18–25 reported past-year hallucinogen use.
- Approximately 6.6 million adults age 26 or older reported past-year hallucinogen use.
- Approximately 6.3 million adults age 18 or older reported past-year psilocybin use.
- Approximately 1.3 million adults age 18 or older reported past-year LSD use.
- Approximately 1.9 million adults age 18 or older reported past-year MDMA/Ecstasy use.
These statistics use the broad SAMHSA hallucinogen category, which includes drugs with very different pharmacological profiles. The numbers therefore should not be interpreted as though nine million Americans all used LSD or all had a hallucinogen-related substance use disorder.
Can You Overdose on Hallucinogens?
Yes, although what “overdose” looks like depends heavily on the substance involved.
Classic psychedelics such as LSD and psilocybin generally have a different direct toxicity profile from opioids, cocaine, PCP, ketamine, or MDMA. Death caused solely by acute LSD, psilocybin, or mescaline toxicity is uncommon, but severe psychological effects, accidents, unsafe behavior, self-harm, and polysubstance exposure can still produce serious or fatal outcomes. (DEA)
Possible severe effects of hallucinogen intoxication can include:
- Extreme fear or panic
- Severe agitation
- Paranoia
- Confusion
- Disorientation
- Hallucinations
- Delusions
- Dangerous impulsive behavior
- Loss of coordination
- Accidental injury
- Psychosis
- Self-harm or suicidal behavior
Risks Differ by Substance
LSD: High doses can cause profound perceptual disturbance, panic, paranoia, severe agitation, or psychotic symptoms.
Psilocybin: Large or unpredictable doses can cause intense fear, confusion, panic, hallucinations, and dangerous behavior. Mistaking a poisonous mushroom for a psilocybin-containing mushroom creates an entirely separate poisoning risk.
PCP: High doses can cause severe agitation, psychosis, seizures, abnormal blood pressure or heart rate, unconsciousness, coma, and potentially death.
Ketamine: High-dose exposure can cause profound dissociation, unconsciousness, dangerously slowed breathing, and other medical complications. (DEA)
MDMA: MDMA has significant stimulant effects and can cause dangerous overheating, dehydration, electrolyte problems, cardiovascular complications, seizures, or other medical emergencies.
Because the category is so broad, a statement such as “fatal hallucinogen overdoses are rare” should not be applied equally to PCP, ketamine, MDMA, and classic psychedelics.
When Is Hallucinogen Use a Medical Emergency?
Call 911 when someone who has used a hallucinogenic or dissociative drug:
- Cannot be awakened
- Has abnormal or dangerously slow breathing
- Experiences a seizure
- Loses consciousness
- Develops severe agitation or violent behavior
- Appears dangerously overheated
- Is severely confused or delirious
- Experiences severe chest pain
- Is hallucinating and may harm themselves or others
- Displays suicidal behavior
- Otherwise appears medically unstable
Acute drug poisoning or severe psychosis may require emergency hospital treatment before addiction treatment is appropriate.
Hallucinogen Persisting Perception Disorder and Other Long-Term Effects
Some people experience persistent perceptual symptoms after a hallucinogenic drug is no longer active.
Hallucinogen Persisting Perception Disorder (HPPD) can involve recurring visual disturbances or fragments of a prior hallucinogenic experience in the absence of current drug use.
Possible experiences can include:
- Visual trails
- Halos around objects
- Flashes of color
- Geometric patterns
- Distortion of size or movement
- Recurring visual phenomena sometimes described as “flashbacks”
The DEA notes that HPPD can appear weeks or months after hallucinogen use and that its occurrence can be unpredictable. (DEA)
Persistent psychosis has also been reported in connection with hallucinogen use, although these effects are uncommon and can be difficult to separate from underlying psychiatric vulnerability or other drug exposure.
Anyone experiencing prolonged perceptual changes, paranoia, hallucinations, severe anxiety, or other psychiatric symptoms after drug use should receive an appropriate medical or mental-health evaluation.
Do Hallucinogens Cause Withdrawal?
There is no single hallucinogen withdrawal syndrome because the category includes drugs with very different pharmacology.
Classic Psychedelics
LSD, psilocybin, mescaline, and related classic psychedelics generally do not produce the predictable physical withdrawal syndrome seen with alcohol, benzodiazepines, or opioids.
Some people may experience emotional distress, fatigue, anxiety, or difficulty processing an intense experience afterward, but these symptoms should not automatically be labeled a classic drug-withdrawal syndrome.
PCP Withdrawal
PCP is different.
People who repeatedly use PCP can develop tolerance and dependence. MedlinePlus lists PCP withdrawal symptoms including anxiety, agitation, confusion, hallucinations, abnormal muscle activity, increased body temperature, and seizures. (MedlinePlus)
Someone experiencing significant PCP withdrawal may benefit from a structured level of care where physical and psychiatric symptoms can be monitored. Severe symptoms may require hospital treatment.
Ketamine and Other Dissociative Drugs
Evidence surrounding a clearly defined ketamine withdrawal syndrome is less established than the evidence for many other substances, but repeated nonmedical use can become compulsive and may be associated with cravings and other symptoms when use stops.
Treatment should therefore focus on what the person has actually been using rather than assuming that “hallucinogen withdrawal” always means the same thing.
Hallucinogen Detox and Stabilization in Tennessee
Not everyone who stops LSD, psilocybin, or another classic psychedelic requires a medical detox.
Brooks can provide assessment, detox, and stabilization when a person’s actual clinical presentation makes that level of care appropriate. This may be particularly relevant when:
- PCP or another dissociative drug is involved
- Multiple substances are being used
- Alcohol or benzodiazepine dependence is also present
- Psychiatric symptoms appropriate for the substance use treatment setting require monitoring
- Someone has experienced repeated severe intoxication
- Medical problems complicate substance use
- There is uncertainty about what an illicit drug contained
- The person does not have a safe environment in which to stabilize
Medical instability or severe psychiatric symptoms may require emergency or hospital care before admission.
What Happens During Hallucinogen Stabilization?
Assessment may consider:
- Which drug or drugs were used
- Frequency of use
- Dose when known
- Route of administration
- Time since last use
- History of severe intoxication or “bad trips”
- Persistent visual symptoms
- Hallucinations or paranoia
- Suicidal thoughts
- Previous psychosis
- PCP or ketamine use
- MDMA or stimulant exposure
- Alcohol or benzodiazepine use
- Opioid exposure
- Medical conditions
- Current medications
- Mental health history
- Previous addiction treatment
The appropriate treatment plan can then be built around the actual risk rather than the broad word “hallucinogen.”
Psychedelic Research Is Not the Same as Recreational Hallucinogen Use
Research into psychedelics and dissociative drugs has expanded considerably, and several substances are being studied for possible therapeutic applications.
That research does not mean that an unregulated psychedelic bought online, at a party, or through an illicit market is equivalent to a medication used in a controlled clinical study.
Ketamine is a useful example.
FDA-approved ketamine is available as an injectable anesthetic. A related medication, esketamine (Spravato®), is FDA approved for certain forms of depression and must be administered through a controlled medical program because of risks including sedation, dissociation, respiratory depression, and misuse. FDA-approved ketamine itself is not approved as a psychiatric medication, even though clinicians may use ketamine off-label in some medical settings. (FDA)
Medical supervision, pharmaceutical manufacturing standards, patient selection, dosing, emergency preparation, and clinical monitoring distinguish legitimate medical care from uncontrolled recreational use.
What Are My Options for a Hallucinogen Addiction Treatment Center in Tennessee?
For those struggling with hallucinogen addiction or problematic use, finding an effective treatment center can be an important step toward lasting recovery.
Brooks Healing Center provides a structured, supportive environment between Nashville and Chattanooga in Normandy, Tennessee where patients can focus on recovery without many of the distractions and triggers of everyday life.
For clinically appropriate patients, residential treatment can address the behavioral and psychological patterns connected with repeated hallucinogen, PCP, ketamine, MDMA, or polysubstance use.
Brooks uses a range of individualized therapeutic approaches.
Cognitive Behavioral Therapy
Cognitive Behavioral Therapy (CBT) helps people identify and change thoughts, behaviors, triggers, and coping patterns associated with substance use.
For someone struggling with repeated hallucinogen use, CBT may help address:
- Triggers
- Cravings
- Impulsive decisions
- Escapism
- Anxiety
- High-risk environments
- Social pressure
- Relapse patterns
- Alternative coping strategies
Experiential Therapy
Experiential Therapy uses structured therapeutic experiences to help patients process emotions, increase self-awareness, improve communication, and practice healthier coping strategies.
Trauma-Informed Care
Trauma-Informed Therapy recognizes that trauma can influence substance use for some people.
Treatment should not assume that every case of hallucinogen misuse is caused by trauma, but when trauma is relevant, a trauma-informed approach can help provide a safer treatment environment and address related emotional symptoms.
Brainspotting
Brainspotting Therapy may be incorporated when clinically appropriate as one part of an individualized treatment plan.
It is an adjunctive therapeutic modality that may be used when relevant trauma or emotional concerns are part of the broader clinical picture. It should not be presented as a proven stand-alone treatment for hallucinogen addiction.
12-Step Recovery Support
12-Step Recovery Support can provide community, accountability, structure, and continuing recovery principles alongside formal clinical care.
Hallucinogen Use and Co-Occurring Mental Health Conditions
Hallucinogen use can overlap with anxiety, depression, PTSD, bipolar symptoms, psychosis, personality disorders, and other mental-health concerns.
The relationship is not always straightforward.
Some people use hallucinogens in an attempt to escape emotional pain or change how they feel. In other cases, an intense drug experience may trigger or worsen:
- Panic
- Severe anxiety
- Paranoia
- Hallucinations
- Delusional thinking
- Depression
- Trauma-like symptoms
- Persistent perceptual changes
Brooks treats substance use disorders and supports co-occurring mental health symptoms when they can be safely managed within our substance use treatment setting. Individuals needing primary psychiatric hospitalization or a higher level of psychiatric care may require referral to an appropriate provider.
Patients experiencing persistent hallucinations, paranoia, or other psychotic symptoms may also require evaluation for drug-induced psychosis.
Severe psychosis, suicidal thinking, dangerous behavior, or inability to distinguish reality requires urgent professional evaluation. Call 911 for an immediate danger to life; call or text 988 for crisis support.
Residential Hallucinogen Addiction Treatment in Tennessee
Residential treatment provides a highly structured environment for people whose substance use and safely manageable co-occurring mental-health symptoms require greater support.
At Brooks, residential treatment provides 24/7 staff support while patients participate in therapy, recovery education, peer support, relapse-prevention planning, and individualized treatment, with access to medical care as needed.
Residential treatment may be particularly useful when someone:
- Repeatedly returns to substance use
- Uses multiple drugs
- Has co-occurring mental-health symptoms that can be safely addressed in this level of care
- Experiences dangerous intoxication episodes
- Has an unstable recovery environment
- Needs separation from a social environment centered on substance use
- Has struggled to maintain recovery at a lower level of care
The goal is not simply to keep someone away from hallucinogens while they are inside a treatment facility. Treatment should help patients develop coping skills and recovery support that remain useful after access to substances and everyday stressors return.
Continuing Care After Residential Hallucinogen Treatment
Recovery does not necessarily end when residential treatment is completed.
Some patients benefit from continued structure as they begin returning to everyday life and practicing recovery skills outside a 24-hour treatment environment.
Partial Hospitalization Program
Brooks’ Partial Hospitalization Program provides intensive daytime treatment at the Normandy campus for medically stable patients who continue to need substantial clinical support.
PHP may include therapy, recovery education, relapse-prevention planning, medication management when clinically appropriate, and support for co-occurring mental-health symptoms that can be safely managed within this substance use treatment setting.
Eligible patients who need a structured place to live while participating in PHP may use Brooks’ supportive housing in Tullahoma.
Sober Living
For eligible individuals who no longer require intensive clinical treatment but continue to benefit from accountability and a substance-free recovery environment, Brooks provides sober living in Tullahoma.
Sober living can provide peer accountability, routine, substance-free housing, and increasing independence while work, relationships, finances, and other everyday responsibilities return.
Why Choose Brooks for Hallucinogen Addiction Treatment in Tennessee?
Brooks Healing Center provides hallucinogen and substance use treatment between Nashville and Chattanooga in Normandy, Tennessee.
Brooks is accredited by The Joint Commission and licensed by the Tennessee Department of Mental Health and Substance Abuse Services. View Brooks licensure.
Depending on clinical needs, treatment may include:
- Assessment and stabilization
- Residential addiction treatment
- Co-occurring symptom support appropriate for the substance use treatment setting
- Partial Hospitalization Program
- Supportive PHP housing
- Sober living
- Continuing recovery planning
Treatment is based on the individual substance, pattern of use, mental-health needs, other drugs involved, and the level of structure needed rather than treating every hallucinogenic drug as though it produces the same clinical picture.
Does Insurance Cover Hallucinogen Addiction Treatment?
Many health insurance plans provide benefits for substance use disorder treatment, although coverage depends on the individual policy, medical necessity, recommended level of care, network status, deductible, coinsurance, and authorization requirements.
Brooks’ admissions team can verify your insurance benefits before treatment and explain the information provided by your insurance carrier.
Insurance verification does not guarantee payment, but it can help patients and families understand what benefits may be available before admission.
Start Healing Today. We’ll Help You Every Step of the Way.
Hallucinogen-related problems do not always look like opioid, alcohol, or stimulant addiction. Some people seek help because repeated psychedelic use has become disruptive, while others are struggling with PCP, ketamine, polysubstance use, frightening intoxication episodes, persistent perceptual symptoms, or worsening mental health.
Brooks Healing Center provides individualized substance use treatment in Tennessee through assessment and stabilization when appropriate, residential addiction treatment, behavioral therapy, support for co-occurring mental health symptoms appropriate for our substance use treatment setting, PHP, supportive housing, sober living, and continued recovery planning.
Call Brooks Healing Center at (931) 486-8824 to speak with admissions.
Frequently Asked Questions About Hallucinogen Rehab in Tennessee
What Is the Difference Between Hallucinogen Abuse and Addiction?
Hallucinogen abuse or misuse involves a harmful pattern of using substances that alter perception, mood, or cognition, such as LSD, psilocybin, PCP, or ketamine.
Problematic use can interfere with health, relationships, work, school, judgment, or everyday functioning.
Addiction or a substance use disorder involves a broader pattern in which drug use becomes difficult to control or continues despite significant consequences.
Classic psychedelics are less likely to produce the physical dependence pattern seen with alcohol, opioids, or benzodiazepines, but this should not be generalized to every dissociative or hallucinogenic drug. PCP, for example, can produce dependence and withdrawal.
Can Hallucinogens Cause Long-Term Effects?
Yes, although serious persistent effects are uncommon and risk varies by drug and individual.
Possible longer-term problems include persistent anxiety, paranoia, mood symptoms, recurring perceptual disturbances, or Hallucinogen Persisting Perception Disorder (HPPD).
Some people can also experience persistent psychotic symptoms after drug use, particularly when underlying vulnerability or multiple substances are involved. (DEA)
How Does Brainspotting Assist in Hallucinogen Addiction Treatment?
Brainspotting is not a medication or direct treatment for the pharmacological effects of hallucinogens.
It is a therapeutic approach that may be used when trauma, emotional distress, or other concerns are relevant to a patient’s individualized recovery plan.
At Brooks, Brainspotting Therapy may be incorporated alongside other therapies when clinically appropriate. It is not a proven stand-alone treatment for hallucinogen addiction.
What Are the Benefits of Residential Hallucinogen Addiction Treatment in Tennessee?
Residential treatment provides a structured environment removed from many of the triggers and opportunities for substance use present in everyday life.
Patients can participate in therapy, recovery education, co-occurring symptom support, relapse-prevention planning, group treatment, and other individualized services while living in a substance-free setting.
Residential care may be particularly useful for people with severe or repeated substance use, polysubstance use, co-occurring symptoms that can be safely managed within the substance use treatment setting, or previous difficulty maintaining recovery at a lower level of care.
Can Hallucinogen Addiction Treatment Address Co-Occurring Mental Health Issues?
Yes.
Brooks treats substance use disorders and supports co-occurring symptoms such as anxiety, depression, and trauma-related concerns when they can be safely managed within the addiction-treatment setting.
Integrated support helps the clinical team evaluate how substance use and mental health interact instead of assuming that one problem exists independently from the other. Primary psychiatric hospitalization or a higher level of psychiatric care may require referral to an appropriate provider.
Are Hallucinogens Physically Addictive?
There is no one answer for every drug in the category.
Classic psychedelic drugs such as LSD and psilocybin generally do not produce the same pattern of physical dependence and withdrawal associated with alcohol, opioids, or benzodiazepines.
Dissociative drugs such as PCP and ketamine have different abuse and dependence profiles. PCP can cause both addiction and withdrawal symptoms. (MedlinePlus)
Do You Need Detox for LSD or Mushrooms?
Not usually for uncomplicated cessation of a classic psychedelic by itself.
LSD and psilocybin generally do not produce a medically dangerous withdrawal syndrome requiring detox in the way alcohol or benzodiazepines can.
Structured stabilization may still be appropriate when there are psychiatric symptoms, polysubstance use, PCP or other dissociative-drug involvement, medical concerns, or an unsafe recovery environment. Severe psychiatric symptoms or medical instability may require hospital care.
Can PCP Cause Withdrawal?
Yes.
PCP withdrawal can include anxiety, agitation, confusion, hallucinations, abnormal muscle activity, elevated body temperature, and seizures in some cases. (MedlinePlus)
Significant symptoms warrant professional medical evaluation.
Is Ketamine Addictive?
Ketamine can be misused and can develop into a problematic or compulsive pattern of use.
Repeated exposure can also cause significant physical complications, including urinary and bladder injury. Ketamine’s legitimate medical use should not be confused with uncontrolled nonmedical use. (Ketamine prescribing information)
Is Medical Ketamine Therapy the Same as Using Ketamine Recreationally?
No.
FDA-approved ketamine is an injectable anesthetic administered under medical supervision. FDA-approved esketamine is a separate nasal medication used for specific depression indications under a restricted safety program.
Illicit or unregulated ketamine does not have the same manufacturing controls, dosing oversight, patient screening, or clinical monitoring. (FDA)
Can Hallucinogens Cause Psychosis?
They can produce acute psychotic symptoms such as severe paranoia, hallucinations, delusions, or disorganized thinking.
In most cases, acute drug effects resolve as intoxication wears off, but persistent psychiatric symptoms can occur and require professional evaluation.
Anyone who cannot distinguish reality, appears dangerous to themselves or others, or develops persistent hallucinations or paranoia should receive prompt clinical care. Call 911 if there is immediate danger.
Does Brooks Provide Hallucinogen Addiction Treatment in Tennessee?
Yes.
Brooks provides treatment for clinically appropriate adults struggling with problematic hallucinogen, dissociative-drug, or polysubstance use between Nashville and Chattanooga in Normandy, Tennessee.
The recommended level of care depends on the actual substance involved, frequency and pattern of use, medical needs, psychiatric symptoms, other substances, treatment history, and recovery environment.
Sources
Cleveland Clinic. (2023, April 18). Hallucinogens. https://my.clevelandclinic.org/health/articles/6734-hallucinogens-lsd-peyote-psilocybin-and-pcp
MedlinePlus. (2024, May 4). Substance use—Phencyclidine (PCP). U.S. National Library of Medicine. https://medlineplus.gov/ency/patientinstructions/000797.htm
National Institute on Drug Abuse. (2023, April). Psychedelic and dissociative drugs. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs
National Institute on Drug Abuse. (n.d.). MDMA (Ecstasy/Molly). https://nida.nih.gov/research-topics/mdma-ecstasy-molly
Par Health USA, LLC. (2026, March 27). Ketalar (ketamine hydrochloride) injection [Prescribing information]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063
Substance Abuse and Mental Health Services Administration. (2026a). 2025 National Survey on Drug Use and Health: Detailed tables. https://www.samhsa.gov/data/sites/default/files/reports/rpt57152/2025-nsduh-detailed-tabs/2025-nsduh-detailed-tables.htm
Substance Abuse and Mental Health Services Administration. (2026b). Key substance use and mental health indicators in the United States: Results from the 2025 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/reports/rpt57150/2025-nsduh-annual-national-html/2025-nsduh-annual-national.htm
U.S. Drug Enforcement Administration. (2025, August 21). Hallucinogens [Drug fact sheet]. https://www.dea.gov/factsheets/hallucinogens
U.S. Drug Enforcement Administration. (2025, January 22). Ketamine [Drug fact sheet]. https://www.dea.gov/factsheets/ketamine
U.S. Food and Drug Administration. (2023, October 10). FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. [Archived FDA safety alert]. https://web.archive.org/web/20260530025451/https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine